FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.582,74 +3.244,85 (+5,86%)
Cytokinetics, Incorporated (CYTK)
Dopo ore:
| Chiusura precedente | 64,34 |
| Aperto | 66,08 |
| Denaro | 65,23 x 400 |
| Lettera | 65,35 x 400 |
| Min-Max giorno | 65,00 - 66,61 |
| Intervallo di 52 settimane | 25,98 - 110,25 |
| Volume | |
| Media Volume | 1.966.269 |
| Capitalizzazione | 6,826B |
| Beta (5 anni mensile) | 0,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,45 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 93,88 |
GlobeNewswireCytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
Topline Results from SEQUOIA-HCM Expected by End of YearSOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the HCM Society
- GlobeNewswire
Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company’s cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), including n
- GlobeNewswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.46 per share, which is equal to the closing price of the Company’s common stock
